FDA approves new treatment for HER2-positive late-stage breast Cancer
June 29th 2012The United States Food and Drug Administration (FDA), under its priority review program, recently approved PerjetaTM (pertuzumab), a HER2/neu receptor antagonist indicated in combination with HerceptinR (trastuzumab), another HER2 therapy, and docetaxel for treatment of HER2-positive metastatic breast cancer (BCa) in women who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Read More
FDA finds no major safety issues for compounded 17P
June 29th 2012Analysis by the United States Food and Drug Administration (FDA) of compounded 17α-hydroxyprogesterone caproate (17P) shows the samples meet the potency and total purity standards for Makena, the branded version of the drug. Testing was done on 16 samples of bulk 17P active pharmaceutical ingredients (API) in response to questions from K-V Pharmaceuticals, Makena’s sponsor, about potency and purity of the compounded product.
Read More
New U/S-based tool for prediction of fetal weight and adverse outcomes
June 21st 2012Customized estimated fetal weight (EFW) percentiles based on ultrasound (U/S)-derived EFWs better predict adverse perinatal outcomes than older population-based methods, according to an historic cohort study.
Read More
VBAC or no VBAC? That is the ongoing question
June 7th 2012Shared perception of the safety of a trial of labor after cesarean delivery among all participants appears to be the deciding factor in whether that option is offered, concludes a report by the Agency for Healthcare Research and Quality.
Read More
History of fast labor may preclude elective induction
June 1st 2012Women who undergo elective induction of labor for a history of fast labor continue the trend of delivering in about half the time of other women, but the benefit of induction is small, a study from the Summa Health System reports.
Read More
LARCs have advantage in preventing teen pregnancy
June 1st 2012Long-acting reversible contraceptives (LARCs) are significantly more effective than oral contraceptive pills, rings, or patches in preventing unintended pregnancy in adolescent girls and young women, a large prospective cohort study from Washington University School of Medicine reports.
Read More
Ob/gyns should screen for CVD, cardiologists advise
June 1st 2012According to a study presented at the 2012 Annual Meeting of the Society for Cardiovascular Angiography and Interventions, many women are unaware of their risk for cardiovascular disease (CV), but a screening tool completed during their annual ob/gyn examination could change that.
Read More
Ovarian Ca: Predictive tool for outcomes promising
June 1st 2012A new algorithm based on gene expression data for 151 DNA repair genes can identify outcomes and response to platinum-based chemotherapy in patients with epithelial ovarian cancer, researchers at the Dana-Farber Cancer Institute report.
Read More